Financial Review: Amylyx Pharmaceuticals (AMLX) versus The Competition

Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Rating) is one of 996 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its competitors? We will compare Amylyx Pharmaceuticals to related businesses based on the strength of its dividends, risk, analyst recommendations, valuation, earnings, profitability and institutional ownership.

Profitability

This table compares Amylyx Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-86.40%	-73.98%
Amylyx Pharmaceuticals Competitors	-3,380.54%	-239.13%	-35.26%

Valuation & Earnings

This table compares Amylyx Pharmaceuticals and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Amylyx Pharmaceuticals	$22.23 million	-$198.38 million	-8.44
Amylyx Pharmaceuticals Competitors	$8.24 billion	$225.71 million	-3.98

Amylyx Pharmaceuticals’ competitors have higher revenue and earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of recent recommendations for Amylyx Pharmaceuticals and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	0	1	5	0	2.83
Amylyx Pharmaceuticals Competitors	4346	15319	41771	733	2.63

Amylyx Pharmaceuticals currently has a consensus price target of $50.50, indicating a potential upside of 74.50%. As a group, “Pharmaceutical preparations” companies have a potential upside of 101.11%. Given Amylyx Pharmaceuticals’ competitors higher possible upside, analysts plainly believe Amylyx Pharmaceuticals has less favorable growth aspects than its competitors.

Risk & Volatility

Amylyx Pharmaceuticals has a beta of -0.84, meaning that its stock price is 184% less volatile than the S&P 500. Comparatively, Amylyx Pharmaceuticals’ competitors have a beta of 0.84, meaning that their average stock price is 16% less volatile than the S&P 500.

Insider and Institutional Ownership

70.6% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 40.5% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 12.7% of Amylyx Pharmaceuticals shares are owned by insiders. Comparatively, 15.6% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Amylyx Pharmaceuticals competitors beat Amylyx Pharmaceuticals on 8 of the 13 factors compared.

About Amylyx Pharmaceuticals

(Get Rating)

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.